绿叶制药多款创新药品成功入医保目录
财中社11月28日电绿叶制药（02186）发布自愿性公告，宣布多款创新产品成功纳入2024年国家医保药品目录。其中，若欣林®（盐酸托鲁地文拉法辛缓释片）首次纳入，百拓维®（注射用戈舍瑞林微球）新增乳腺癌适应症，力扑素®（注射用紫杉醇脂质体）则纳入常规目录。新版国家医保药品目录将于2025年1月1日起正式实施。
此次产品进入医保目录将显著提升患者的用药可及性，减轻治疗负担，同时加速公司产品的商业化进程，进一步提升创新回报。若欣林®是中国首个自主研发的治疗抑郁症的创新药，已有超过2.5万名患者受益。百拓维®和力扑素®则分别用于前列腺癌和乳腺癌的治疗，力扑素®是全球唯一上市的紫杉醇脂质体制剂，具有良好的安全性和疗效。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10